At week 52 clinical remission according to CDAI [US analysis] occurred in 55% of the 180-mg group, 52% in the 360-mg group compared to 41% in placebo; in the outside US analysis, clinical remission, defined on stool frequency and abdominal pain, occurred in 46% and 52% vs 40% in the same groups, but the difference between the 180-mg group and placebo did not reach statistical significance.
1
—
—